Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,10€(−82,29%). Der Median liegt bei +1,10€(−82,29%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)» Mehr auf globenewswire.com
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).» Mehr auf zacks.com
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.» Mehr auf zacks.com

Im letzten Quartal hatte Seres Therapeutics Inc einen Umsatz von 0,00€ und ein Nettoeinkommen von 30,21 Mio€